Evidence map›Paper›PMID 42003796›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Engineering Oncolytic Virus-Armed Macrophages for Enhanced Cancer Immunotherapy.

Jilong Wang, Ning Lu, Zhuo Yan, Luyi Ye, Luyao Bai, Shanshan Yuan, Yuting Zhu, Yiru Xiong, Yongheng Bai, Yaping Chen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jilong WangJoint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Ning LuJoint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zhuo YanJoint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Luyi YeJoint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Luyao BaiJoint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Shanshan YuanJoint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yuting ZhuJoint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yiru XiongJoint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yongheng BaiJoint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yaping ChenOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain, Health), Wenzhou, Zhejiang, China.
Junjie DengJoint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China.

Funding

Discipline Cluster of Oncology of Wenzhou Medical University in China z3-2023034Huadong Medicine Joint Fund of Zhejiang Provincial Natural Science Foundation of China LHDMZ26H160004National Natural Science Foundation of China 32101127Scientific Research Project of Wenzhou Medical University QTJ25045Wenzhou High Level Innovation Team Program 2024R2001Zhejiang Province Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation G2023006Zhejiang Province Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation G2023014Zhejiang Provincial Department of Science and Technology 2025R01025
6 · The paper itself

Abstract

Macrophage-based immunotherapy holds great promise for solid tumors but is limited by impaired phagocytosis and unstable M1-type polarization due to immunosuppressive tumor microenvironments. Here, we develop engineered macrophages by conjugating oncolytic adenovirus (OA)-loaded zeolitic imidazolate framework-8 (ZIF-8) onto macrophage surfaces via bioorthogonal chemistry (ZIFOA-M). This platform leverages localized viral delivery to selectively downregulate "don't eat me" signals (CD47 and CD24) on tumor cells, thereby restoring macrophage phagocytic capacity. Moreover, viral replication within tumors induces immunogenic cell death, releasing major damage-associated molecular patterns (DAMPs) that sustain M1-type polarization and promote durable antitumor immunity. ZIFOA-M also enhances tumor antigen presentation, eliciting robust tumor-specific T cell responses. Our strategy integrates phagocytosis restoration, microenvironment remodeling, and adaptive immune activation in a single, localized platform. ZIFOA-M offers a complementary and translatable approach to overcome key barriers in macrophage-based cancer immunotherapy.

Indexed as

ImmunotherapyMacrophagesNeoplasmsOncolytic VirotherapyOncolytic VirusesAdenoviridaeAnimalsHumansMiceTumor Microenvironmentanti‐tumorarmored macrophageimmunotherapyOncolytic adenovirus

Identifiers

PMID42003796
PMCPMC13335506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.